Skip to content

Comparative Buccal Single Cell Analysis in House Dust Mite Sublingual Immunotherapy Responder and Non- responder

Comparative Buccal Single Cell Analysis in House Dust Mite Sublingual Immunotherapy Responder and Non- responder

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20251105002
Enrollment
20
Registered
2025-11-05
Start date
2025-06-26
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Buccal single-cell analysis in moderate to severe house dust mite-induced allergic rhinitis receiving sublingual immunotherapy

Interventions

Lebel score decrease equal or more than 3 after 4 months of SLIT,Lebel score decrease less than 3 after 4 months of SLIT
Basic Science,Basic Science
Responder ,Non-responder

Sponsors

Chulalongkorn University
Lead Sponsor
The Allergy, Asthma &amp
Collaborator
Immunology Association of Thailand (AAIAT)
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.House dust mite-induced allergic rhinitis (According to the ARIA definition) Sensitization to house dust mite (Any one of two tests) - Wheal size of skin prick test to Dp or Df >= 3 mm - serum Der p-specific IgE or Der f-specific IgE >0.35 kUA/L 2.Moderate to severe symptoms (According to the ARIA definition) 3.Patients are willing to undergo SLIT

Exclusion criteria

Exclusion criteria: 1.Asthma 2.FEV1 < 70% predicted 3.Pregnancy 4.Have gotten AIT in the past 5 years 5.Nasal surgery within 3 months 6.on immunosuppressive drugs 7.Cancer 8.Systemic diseases effecting immune system such as diabetes mellitus, chronic liver disease, chronic kidney disease, malnutrition etc. 9.Smoking 10.Regular alcohol drinking (current light to heavier drinker) 11.Dental carries, chronic ulcer or other diseases of oral or buccal mucosa 12.Cosensitization with seasonal allergen, pet allergen 13.Food allergy 12.Bleeding tendency (Including the use of antiplatelet and anticoagulant)

Design outcomes

Primary

MeasureTime frame
Gene expression in oral mucosal cells between responders and non-responders Pre-treatment peroid Single-cell RNA sequencing

Secondary

MeasureTime frame
Changes in gene expression in oral mucosal cells before and after HDM SLIT Pre-treatment and Post-treatment periods Single-cell RNA sequencing

Countries

Thailand

Contacts

Public ContactHiroshi Chantaphakul

Chulalongkorn university

hiroshi.c@chula.ac.th022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026